Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Bryce A. Harrison"'
Publikováno v:
Burger's Medicinal Chemistry and Drug Discovery
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::709e1f572fba44eb1cce61fd940bfe33
https://doi.org/10.1002/0471266949.bmc277
https://doi.org/10.1002/0471266949.bmc277
Autor:
Deirdre Murphy, Sudarshan Kapadnis, Bryce Alden Harrison, Hilliary E Van Voorhies, Jean-Francois Blain, Emily A. Freeman, Jeffrey S. Moffit, Scott Nolan, Melody Wen, Lori Hrdlicka, Duane A. Burnett, Matthew Gregory Bursavich, Gerhard Koenig, Don Costa, Holger Patzke, Raksha A. Acharya, Cuyue Tang, Hong Jin
Publikováno v:
Journal of medicinal chemistry. 64(19)
The recent approval of aducanumab for Alzheimer's disease has heightened the interest in therapies targeting the amyloid hypothesis. Our research has focused on identification of novel compounds to improve amyloid processing by modulating gamma secre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34f9b0147cc5066edcb7f9badfeea7b3
https://pubmed.ncbi.nlm.nih.gov/34550687
https://pubmed.ncbi.nlm.nih.gov/34550687
Autor:
Wenxue Wu, Lauren E. Sirois, Bryce Alden Harrison, Ngiap-Kie Lim, Matthew Mangzhu Zhao, Mark S. Bednarz
Publikováno v:
Organic Process Research & Development. 23:45-61
Process development for the synthesis of a locally acting sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor, LX2761, a drug candidate for the treatment of diabetes mellitus, is described. ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bd6520429d94d058e46a42dac21dd4e6
https://doi.org/10.1021/acs.oprd.8b00325
https://doi.org/10.1021/acs.oprd.8b00325
Autor:
Adrian S. Ray, Troast Dawn M, James E. Dowling, Vinod Yadav Yadav, Eugene Nebelitsky, Lippa Blaise S, Andrew K. Sullivan, Fu-Yang Lin, Dan Cui, Dooyoung Lee, Lia Luus, Megan Krumpoch, Laura Cappellucci, Terence Moy, Bryce Alden Harrison, Rogers Bruce N, Natalia J. Reszka-Blanco, Meghan Monroy, Qi Qiao, Elizabeth Gwara
Publikováno v:
Cancer Research. 81:1559-1559
Introduction We explored whether integrin αvβ8 inhibition potentiates immune checkpoint blockade (ICB) in syngeneic orthotopic models of breast cancer. Integrin αvβ8 mediates cell type specific and tissue localized activation of TGFβ1/3 to regul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::522bcc8006802041287d1bc20657b88c
https://doi.org/10.1158/1538-7445.am2021-1559
https://doi.org/10.1158/1538-7445.am2021-1559
Autor:
Suma Gopinathan, Kenneth G. Carson, Alan G. E. Wilson, Zhi-Ming Ding, Bryce Alden Harrison, Damaris S. Diaz, Angela L. Harris, Debra Bruce, Nicole Cathleen Goodwin, Emily O’Neill, David R. Powell, Melinda Smith, Eric Strobel, David B. Rawlins, Wendy Xiong, Ling Li, Andrea Y. Thompson, Mary Thiel, Faika Mseeh
Publikováno v:
Journal of Medicinal Chemistry. 60:710-721
The increasing number of people afflicted with diabetes throughout the world is a major health issue. Inhibitors of the sodium-dependent glucose cotransporters (SGLT) have appeared as viable therapeutics to control blood glucose levels in diabetic pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8541b1a58e42776d5a5b4773e40351f7
https://doi.org/10.1021/acs.jmedchem.6b01541
https://doi.org/10.1021/acs.jmedchem.6b01541
Autor:
Bryce Alden Harrison, Lakshman Samala, Nita Patel, Zheng Y. Almstead, N. Andrew Whitlock, Ross Mabon, Dennis S. Rice, Nicole Cathleen Goodwin, Beth McKnight, Yulian Zhang, Jason P. Healy, Shuli Wang, Suma Gopinathan, Gardyan Michael Walter, David B. Rawlins, Alan Wilson, Terry R. Stouch, Ying Liu, Brian D. Hamman, Brett A. Marinelli, Hugh Alfred Burgoon
Publikováno v:
ACS Medicinal Chemistry Letters. 6:84-88
The structure of LX7101, a dual LIM-kinase and ROCK inhibitor for the treatment of ocular hypertension and associated glaucoma, is disclosed. Previously reported LIM kinase inhibitors suffered from poor aqueous stability due to solvolysis of the cent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8cd87df001b841d60f0512718b8b7ce9
https://doi.org/10.1021/ml500367g
https://doi.org/10.1021/ml500367g
Autor:
Holger Patzke, Cuyue Tang, Gerhard Koenig, Hong Jin, Lori Hrdlicka, Duane A. Burnett, Sudarshan Kapadnis, Don Costa, Hilliary Hodgdon, Emily A. Freeman, Jean-Francois Blain, Jeffrey S. Moffit, Melody Wen, Bryce Alden Harrison, Matthew Gregory Bursavich, Raksha A. Acharya, Deirdre A. Murphy, Scott Nolan
Publikováno v:
Journal of medicinal chemistry. 60(6)
Herein we describe the design, synthesis, and evaluation of a novel series of oxadiazine-based gamma secretase modulators obtained via isosteric amide replacement and critical consideration of conformational restriction. Oxadiazine lead 47 possesses
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9482321eb4d1ebfec5e8c96be975c48
https://pubmed.ncbi.nlm.nih.gov/28230986
https://pubmed.ncbi.nlm.nih.gov/28230986
Autor:
Alan Wilson, Angela L. Harris, Brian Zambrowicz, Wendy Xiong, Christopher M. DaCosta, David R. Powell, Bryce Alden Harrison, Nicole Cathleen Goodwin, Melinda Smith, Sabrina Jeter-Jones, Andrea Y. Thompson, Eric Strobel, Faika Mseeh, David B. Rawlins, Jennifer Greer, Deon Doree, Suma Gopinathan, Kenneth G. Carson, Zhi-Ming Ding
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 362(1)
LX2761 is a potent sodium/glucose cotransporter 1 inhibitor restricted to the intestinal lumen after oral administration. Studies presented here evaluated the effect of orally administered LX2761 on glycemic control in preclinical models. In healthy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38140540d80f7939267c966c2d73c1da
https://pubmed.ncbi.nlm.nih.gov/28442582
https://pubmed.ncbi.nlm.nih.gov/28442582
Publikováno v:
Journal of medicinal chemistry. 59(16)
The rapidly aging population desperately requires new therapies for Alzheimer's disease. Despite years of pharmaceutical research, limited clinical success has been realized, with several failed disease modification therapies in recent years. On the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09d04138d7622452d9f80edd329774bc
https://pubmed.ncbi.nlm.nih.gov/27007185
https://pubmed.ncbi.nlm.nih.gov/27007185
Autor:
Melanie K. Shadoan, Philip Manton Brown, Arthur T. Sands, Phillip Banks, David R. Powell, Kenny Frazier, Nicole Cathleen Goodwin, Brian Zambrowicz, Ross Mabon, Bryce Alden Harrison, J Bronner, David B. Rawlins, Joel Freiman, Faika Mseeh, Anne Turnage, D Ruff, Alan Wilson
Publikováno v:
Clinical Pharmacology and Therapeutics
Thirty-six patients with type 2 diabetes mellitus (T2DM) were randomized 1:1:1 to receive a once-daily oral dose of placebo or 150 or 300 mg of the dual SGLT1/SGLT2 inhibitor LX4211 for 28 days. Relative to placebo, LX4211 enhanced urinary glucose ex
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b3b3ccb4ff7ef4f5218a92273bcb426
https://doi.org/10.1038/clpt.2012.58
https://doi.org/10.1038/clpt.2012.58